New Clinical Study Finds MolecuLight i: Point-of-Care Imaging Improved Sensitivity of Detecting Bacterial Burden in Surgical Site Wounds by 11-Fold

January 18, 2022 -Authors Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management

TORONTO, ONTARIO – (Jan. 18, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of  “Uncovering

Read More

SWK Holdings Provides $10M USD to MolecuLight to Support Global Commercial Expansion

January 4, 2022 -

DALLAS, TEXAS and TORONTO, ONTARIO – (Jan. 4, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that SWK Holdings Corporation has provided $10M USD structured debt to support MolecuLight’s global commercial expansion. SWK Holdings Corporation (Nasdaq: SWKH) is

Read More

Latest Clinical Evidence Presented at SAWC 2021 Illustrates the Significant Clinical Utility of the MolecuLight Point-of-Care Imaging Platform

October 28, 2021 -7 Clinical Posters and Presentations Highlight the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care Applications

Toronto, ONTARIO and Las Vegas, NEVADA– (October 28, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces the presentation of

Read More

Launch of New MolecuLightDX™ Device to Enable Point-of-Care Imaging of Wounds in New Expanding Market Segments

October 14, 2021 -MolecuLight Platform is Becoming the Standard-of-Care for Real-Time Imaging of Elevated Bacterial Burden in Wounds Across All Wound Care Settings

TORONTO, CANADA – (October 14, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the launch of the MolecuLightDX™,

Read More

Study of 236 patients reveals utility of MolecuLight i:X® in detection and management of wound-related cellulitis

October 12, 2021 -Published results describe use of point-of-care imaging for the early detection and proactive management of wound-related cellulitis

TORONTO, CANADA – (October 12, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication in International Wound

Read More

MolecuLight i:X® Receives FDA 510(k) Clearance for the Device’s Ability to Detect Wounds Likely to Contain Pseudomonas Aeruginosa (PA)

September 23, 2021 -New FDA Clearance Illustrates the Utility of the i:X to Reliably Predict Pseudomonas Aeruginosa, a Bacterial Pathogen that Precludes Wound Healing and Often Evades Conventional Treatment Methods

TORONTO, CANADA – (September 23, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial

Read More

In new publication, 96% of clinicians state that treatment plans informed using the MolecuLight procedure led to improved wound healing – MolecuLight US

July 7, 2021 -Published results provides guidelines to standardize use of fluorescence imaging among wound care providers to enhance the quality of patient care

TORONTO, CANADA – (July 7 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of an

Read More

MolecuLight Signs LMT Surgical as New Distributor for Australia and New Zealand

June 22, 2021 -LMT’s Comprehensive Sales and Support Network to Meet Significant Demand for the MolecuLight i:X® in the Wound Care Community

TORONTO, CANADA and QUEENSLAND, AUSTRALIA– (June 22, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announces it has signed… Read More